# Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05765032/  
OnCo record `nct05765032` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-A1921 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.

## Summary

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05765032 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 220 participants enrolled, started 2022-12-30 and due to reach its primary completion in 2025-04-30. Interventions recorded: SHR-A1921；.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05765032
- Phase: 1/2
- Setting: An Open Label, Multicenter, Phase Ib/II Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT05765032: https://clinicaltrials.gov/study/NCT05765032

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [SHR-A1921](https://onco.cc/drugs/shr-a1921/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct05765032.json